The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2019.1565818
Abstract: Abstract Background: There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who have already been treated… read more here.
Keywords: switching fingolimod; first line; fingolimod versus; cohort ... See more keywords